ArticleCancer science2004
Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
Article in Cancer science, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 71 citations in OpenAlex.
- The role of ferroptosis in cardio-oncology.Archives of toxicology · 2024Review
- Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy.Pharmaceutics · 2023Review
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacological reviews · 2016Review
- Nanotechnology: Future of Oncotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Liposomes as nanomedical devices.International journal of nanomedicine · 2015Review
- Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.AAPS PharmSciTech · 2014Review
- Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Advanced drug delivery reviews · 2014Review
- Antibody-based therapeutics for the treatment of human B cell malignancies.Current allergy and asthma reports · 2013Review
- The big picture on nanomedicine: the state of investigational and approved nanomedicine products.Nanomedicine : nanotechnology, biology, and medicine · 2013Review
- Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.Journal of drug delivery · 2013Article
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.Chemical Society reviews · 2012Review
- Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.International journal of nanomedicine · 2012Article
- Identification of oligopeptides binding to peritoneal tumors of gastric cancer.Cancer science · 2006Article
- Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.International journal of nanomedicine · 2006Review
- Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MCC-465 is an immunoliposome-encapsulated doxorubicin. The liposome is tagged with polyethylene glycol and the F(ab')2 of a monoclonal antibody named GAH, a human antibody obtained by the hybridoma technique. The epitope recognized by GAH is not well characterized, but human gastric, colorectal, and mammary cancer cells were GAH-positive, while the normal counterparts were GAH-negative. Pegylated liposome doxorubicin (PLD) and MCC-465 did not show significant antitumor activity against GAH-negative Caco-2 xenografts. On the other hand, MCC-465 exhibited significantly superior antitumor effects against GAH-positive WiDr-Tc and SW837 xenografts, compared with PLD. Immunohistochemistry with GAH revealed that 94% (100 of 106) of surgical specimens of colorectal cancer were GAH-positive. These results warrant a phase I clinical trial of MCC-465 for patients with metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.